New insider activity at CryoPort ( (CYRX) ) has taken place on March 19, 2025.
In recent transactions involving CryoPort stock, CFO Robert Stefanovich sold 1,659 shares valued at $10,435. Director Jerrell Shelton parted with 4,620 shares, amounting to $29,059. Additionally, CSO Mark W Sawicki sold 2,092 shares for a total of $13,158.
Recent Updates on CYRX stock
CryoPort Inc’s recent financial developments have been marked by a strong performance in its Life Sciences Services division, with notable revenue growth in commercial cell and gene therapies. The company reported a total annual revenue of $228.4 million for 2024, aligning with expectations, and projected a positive outlook for 2025 with anticipated revenues between $240 million and $250 million. Key highlights include a significant improvement in gross margin due to effective cost management and an increase in the number of supported clinical trials. Despite macroeconomic challenges and limited exposure to the China market, CryoPort remains optimistic about its future, driven by strategic growth initiatives and a promising position in the cell and gene therapy sector. The company’s earnings call and subsequent trading activities have reinforced its strong financial outlook and commitment to achieving positive adjusted EBITDA.
More about CryoPort
YTD Price Performance: -18.73%
Average Trading Volume: 360,327
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $319.9M
Questions or Comments about the article? Write to editor@tipranks.com